Ruth Etzioni

Ruth Etzioni is a leading biostatistician in cancer screening evaluation who has provided critical analytical frameworks for interpreting MCED trial results, including the Pathfinder study that evaluated the Galleri test in over 6,600 adults and demonstrated a cancer signal detection rate with 38% PPV and confirmatory diagnostic resolution within a median of 79 days. Her work has developed statistical models for assessing whether MCED screening achieves stage shift and mortality reduction at the population level while accounting for overdiagnosis, lead-time bias, and false positive harms. She has established the analytical standards for evaluating MCED cost-effectiveness. Her rigorous methodology ensures that MCED implementation decisions are evidence-based.